Replies to post #23408 on MMRGlobal, Inc. (fka MMRF)

[Jagman]

Just another fat-figure they can add to the financials....try marketing it...I bet Favrille tried already.

Through May of 2008, pre-merger Favrille had
spent more than $140 million on the creation and development of intellectual
property, which includes clinical trials data, patient samples, patents and
other assets. The Company is working towards entering into licensing agreements
with biopharmaceutical companies, academic institutions, research organizations
and others regarding the use of the assets.